SCHEMBL22598511

SCHEMBL22598511

C=C(S)c1cccc(C(C)C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
CYP3A4 P08684 2/20 0.44
HPGD P15428 2/20 0.44
HDAC4 P56524 2/20 0.44
HDAC8 Q9BY41 2/20 0.44
MDM4 O15151 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
TP53 P04637 1/20 0.44
TYR P14679 1/20 0.44
ALOX15 P16050 1/20 0.44
ALOX12 P18054 1/20 0.44
CA5A P35218 1/20 0.44
HTT P42858 1/20 0.44
MDM2 Q00987 1/20 0.44
CA9 Q16790 1/20 0.44
HDAC2 Q92769 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL299924 0.82 MAPT (0.46) MAPTSMN1; SMN2KDM4EALDH1A1CYP3A4
SCHEMBL31529664 0.82 MAPT (0.46) MAPTSMN1; SMN2KDM4EALDH1A1CYP3A4
SCHEMBL10053239 0.82 RXRA (0.47) MAPTSMN1; SMN2KDM4EALDH1A1CYP3A4
SCHEMBL11885442 0.80 MAPT (0.44) MAPTSMN1; SMN2KDM4EALDH1A1CYP3A4
SCHEMBL16105765 0.78 KAT6A (0.47) MAPTSMN1; SMN2KDM4EALDH1A1CYP3A4
SCHEMBL21308010 0.78 KAT6A (0.47) MAPTSMN1; SMN2KDM4EALDH1A1CYP3A4
SCHEMBL21882575 0.77 KAT6A (0.42) MAPTSMN1; SMN2KDM4EALDH1A1CYP3A4
SCHEMBL16775704 0.77 PTGS1 (0.44) MAPTSMN1; SMN2KDM4EALDH1A1CYP3A4
SCHEMBL21507784 0.77 SMN1; SMN2 (0.42) MAPTSMN1; SMN2KDM4EALDH1A1CYP3A4
SCHEMBL18463069 0.77 SMN1; SMN2 (0.42) MAPTSMN1; SMN2KDM4EALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257414-A1 NUCLEOTIDE ANALOGUES FIRST-CITIZENS BANK & TRUST COMPANY 2023-08-17 US disclosed
US-20220127299-A1 NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF LG ELECTRONICS INC. (KR) 2022-04-28 US disclosed
US-10822653-B1 Nucleotide cleavable linkers and uses thereof Singular Genomics Systems, Inc. (US) 2020-11-03 US disclosed
US-20200340051-A1 NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF FIRST-CITIZENS BANK & TRUST COMPANY 2020-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200340051-A1 NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF NUDT21, CPSF7, DCLRE1A MAPT 3729/4885SMN1; SMN2 1624/4885KDM4E 3403/4885
US-20220127299-A1 NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF NUDT21, CPSF7, DCLRE1A MAPT 3729/4885SMN1; SMN2 1624/4885KDM4E 3403/4885
US-20230257414-A1 NUCLEOTIDE ANALOGUES ITPA, POLB, NUDT1 MAPT 4328/4885SMN1; SMN2 1787/4885KDM4E 4194/4885
US-10822653-B1 Nucleotide cleavable linkers and uses thereof NUDT21, CPSF7, DCLRE1A MAPT 3729/4885SMN1; SMN2 1624/4885KDM4E 3403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.